We recently heard about a  study that is currently recruiting in Aberdeen and Bristol Eye hospitals.   We know of at least one Birdshot patient who has been recruited on this study in the UK and probably there are others.  This link takes you to details about the clinical trial.

The objective  of this study is to test the  Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate, Posterior, or Pan-uveitis.

Adalimumab (also called Humira) is a type of drug known as anti-TNF (anti-tumour necrosis factor). In people with rheumatoid arthritis and some other inflammatory diseases a protein called TNF is overproduced in the body, causing inflammation and damage to bones, cartilage and tissue. Anti-TNF drugs block the action of TNF and so can reduce this inflammation.

Treatment with Adalimumab (Humira)  is self-injected normally every  two weeks. It may be used in combination with antimetabolites or calcineurin inhibitors. Its effect on uveitic activity can be swift, with benefit sometimes seen within days or weeks.  Although not currently licensed for uveitis this drug is already sometimes used in people  who have not responded to other  treatment.

Annie and Rea